Schering Ends Sarasar Lung Cancer Trial, Leaving One Novel Agent In Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Schering-Plough is discontinuing its Sarasar Phase III program in non-small cell lung cancer after an interim analysis suggested the data will not demonstrate efficacy.
You may also be interested in...
Schering Noxafil Phase III
Schering-Plough's triazole antifungal Noxafil (posaconazole oral suspension) shows significantly better results than standard antifungals in a study presented Dec. 8 at the American Society of Hematology meeting. Overall success rate was 42% in patients receiving Noxafil 800 mg/day for up to one year, vs. 26% for standard therapy (p=0.006). Noxafil is one of three launches Schering is anticipating by 2007; the firm also expects to introduce the oncologic Sarasar (lonafarnib) and a fixed combination of Zetia and Zocor, which is pending at FDA with a July user fee goal...
Zetia/Zocor Combo User Fee In July 2004; Genentech Sees Avastin On Time
The user fee deadline for Merck/Schering-Plough’s Zetia/Zocor combination product for cholesterol reduction is July 24, 2004.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011